 |
|
|
| |
Preliminary Efficacy and Safety of Acetyl-CoA Carboxylase Inhibitor GS-0976
in Patients With Compensated Cirrhosis Due To NASH
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Stephen A. Harrison,1 Mazen Noureddin,2 Robert Herring, Jr,3 Peter Ruane,4 Bryan J. McColgan,5 Brian Kirby,5 Cara Nelson,5 Raul Aguilar Schall,5 Catherine Jia,5
G. Mani Subramanian,5 Robert P. Myers,5 Michael Middleton,6 Claude Sirlin,6 Mark Fitch,7 Kelvin Li,7 Marc Hellerstein,7 Eric J. Lawitz8
1Pinnacle Clinical Research, San Antonio, Texas, USA; 2Cedars-Sinai Medical Center, Los Angeles, California, USA; 3Nashville Gastroenterology and Hepatology, PC, Nashville, Tennessee, USA; 4Ruane Clinical Research Group, Inc., Los Angeles; 5Gilead Sciences, Inc., Foster City, California; 6UC San Diego, California; 7University of California, Berkeley; 8Texas Liver Institute, The University of Texas at San Antonio
References
1. Fabbrini E, et al. Gastroenterology 2008;134:424-31; 2. Lambert JE, et al. Gastroenterology 2014;146:726-35; 3. Stiede K, et al. Hepatology 2017;66:324-34; 4. Lawitz EJ, et al, J Hepatol 2017;66:S34; 5. Loomba R,
et al. AASLD 2017, abstr LB-9; 6. Hellerstein MK, et al. Am J Physiol 1999;276:E1146-70; 7. Singh S, et al. Clin Gastroenterol Hepatol 2015;13:440-51; 8. Serai SD, et al. Radiology 2017;285:92-100.
|
| |
|
|
|
|
|
